» Articles » PMID: 31339437

Characterization and Prediction of Positional 4-hydroxyproline and Sulfotyrosine, Two Post-translational Modifications That Can Occur at Substantial Levels in CHO Cells-expressed Biotherapeutics

Abstract

Biotherapeutics may contain a multitude of different post-translational modifications (PTMs) that need to be assessed and possibly monitored and controlled to ensure reproducible product quality. During early development of biotherapeutics, unexpected PTMs might be prevented by identification and characterization together with further molecular engineering. Mass determinations of a human IgG1 (mAb1) and a bispecific IgG-ligand fusion protein (BsAbA) demonstrated the presence of unusual PTMs resulting in major +80 Da, and +16/+32 Da chain variants, respectively. For mAb1, analytical cation exchange chromatography demonstrated the presence of an acidic peak accounting for 20%. A + 79.957 Da modification was localized within the light chain complementarity-determining region-2 and identified as a sulfation based on accurate mass, isotopic distribution, and a complete neutral loss reaction upon collision-induced dissociation. Top-down ultrahigh resolution MALDI-ISD FT-ICR MS of modified and unmodified Fabs allowed the allocation of the sulfation to a specific Tyr residue. An aspartate in amino-terminal position-3 relative to the affected Tyr was found to play a key role in determining the sulfation. For BsAbA, a + 15.995 Da modification was observed and localized to three specific Pro residues explaining the +16 Da chain A, and +16 Da and +32 Da chain B variants. The BsAbA modifications were verified as 4-hydroxyproline and not 3-hydroxyproline in a tryptic peptide map via co-chromatography with synthetic peptides containing the two isomeric forms. Finally, our approach for an alert system based on in-house predictors is presented. This system is designed to prevent these PTMs by molecular design and engineering during early biotherapeutic development.

Citing Articles

Direct glycosylation analysis of intact monoclonal antibodies combining ESI MS of glycoforms and MALDI-in source decay MS of glycan fragments.

Senini I, Tengattini S, Rinaldi F, Massolini G, Gstottner C, Reusch D Commun Chem. 2024; 7(1):203.

PMID: 39261598 PMC: 11390885. DOI: 10.1038/s42004-024-01297-x.


Tyrosine Sulfation at Antibody Light Chain CDR-1 Increases Binding Affinity and Neutralization Potency to Interleukine-4.

DAntona A, Lee J, Zhang M, Friedman C, He T, Mosyak L Int J Mol Sci. 2024; 25(3).

PMID: 38339208 PMC: 10855961. DOI: 10.3390/ijms25031931.


Diagnostic utility of N-terminal TMPP labels for unambiguous identification of clipped sites in therapeutic proteins.

Gunawardena H, Jayatilake M, Brelsford J, Nanda H Sci Rep. 2023; 13(1):18602.

PMID: 37903854 PMC: 10616084. DOI: 10.1038/s41598-023-45446-z.


Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity.

Lietz C, Deyanova E, Cho Y, Cordia J, Franc S, Kabro S MAbs. 2023; 15(1):2259289.

PMID: 37742207 PMC: 10519368. DOI: 10.1080/19420862.2023.2259289.


Revealing charge heterogeneity of stressed trastuzumab at the subunit level.

Spanov B, Baartmans B, Olaleye O, Nicolardi S, Govorukhina N, Wuhrer M Anal Bioanal Chem. 2023; 415(8):1505-1513.

PMID: 36693954 PMC: 9974696. DOI: 10.1007/s00216-023-04547-4.


References
1.
Chen G, Zhang Y, Trinidad J, Dann 3rd C . Distinguishing Sulfotyrosine Containing Peptides from their Phosphotyrosine Counterparts Using Mass Spectrometry. J Am Soc Mass Spectrom. 2018; 29(3):455-462. DOI: 10.1007/s13361-017-1854-1. View

2.
Johnson R, Martin S, Biemann K, Stults J, Watson J . Novel fragmentation process of peptides by collision-induced decomposition in a tandem mass spectrometer: differentiation of leucine and isoleucine. Anal Chem. 1987; 59(21):2621-5. DOI: 10.1021/ac00148a019. View

3.
Frese C, Zhou H, Taus T, Altelaar A, Mechtler K, Heck A . Unambiguous phosphosite localization using electron-transfer/higher-energy collision dissociation (EThcD). J Proteome Res. 2013; 12(3):1520-5. PMC: 3588588. DOI: 10.1021/pr301130k. View

4.
Stone M, Chuang S, Hou X, Shoham M, Zhu J . Tyrosine sulfation: an increasingly recognised post-translational modification of secreted proteins. N Biotechnol. 2009; 25(5):299-317. DOI: 10.1016/j.nbt.2009.03.011. View

5.
van der Burgt Y, Kilgour D, Tsybin Y, Srzentic K, Fornelli L, Beck A . Structural Analysis of Monoclonal Antibodies by Ultrahigh Resolution MALDI In-Source Decay FT-ICR Mass Spectrometry. Anal Chem. 2018; 91(3):2079-2085. PMC: 6365908. DOI: 10.1021/acs.analchem.8b04515. View